Abstract
Purpose: Neoadjuvant chemotherapy (NACT) for early breast cancer (EBC) is indicated for downstaging tumours to allow for breast conserving surgery (BCS). Furthermore, pCR is a surrogate marker for outcome which allows for tailoring of adjuvant treatment to optimise outcomes, especially for Her2(+) and triple negative. This retrospective review aims to provide real world data, regarding downstaging rates, pCR rates and correlation between pCR rates and post-NACT MRI.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
